Fig. 8

ANT2 is a direct target of ETS2. (A-C) Transient transfections were performed by co-transfecting CMV-NULL or CMV-ETS2 with pGL3-ANT2 (-1.0 kb WT) (A), pGL3-ANT2(-0.3 kb WT) (B) or pGL3-ANT2(-0.3 kb Mutant) (C) into BEAS-2B cells (n = 7). After 24 h, relative luciferase activities (RLU) were determined after normalizing to beta-galactosidase activity. WT, wild-type. (D) C57BL/6 mice were i.v. injected with AAV9-NULL or AAV9-ETS2. then OVA treated for 30 days. CHIP assays were performed using lung lysates overexpressing ETS2 and IgG (control) or the ETS2 antibody (n = 4). The DNA enrichment in the ANT2 promoter was determined by qRT-PCR using primers that amplified a fragment between − 227 bp and − 154 bp (D). Statistical analysis was performed using a 2-tailed, unpaired t-test (A-D).**P < 0.01